SK287575B6 - Farmaceutická kompozícia obsahujúca nukleovú kyselinu, použitie nukleovej kyseliny a výrobný artikel obsahujúci farmaceutickú kompozíciu - Google Patents

Farmaceutická kompozícia obsahujúca nukleovú kyselinu, použitie nukleovej kyseliny a výrobný artikel obsahujúci farmaceutickú kompozíciu Download PDF

Info

Publication number
SK287575B6
SK287575B6 SK849-2002A SK8492002A SK287575B6 SK 287575 B6 SK287575 B6 SK 287575B6 SK 8492002 A SK8492002 A SK 8492002A SK 287575 B6 SK287575 B6 SK 287575B6
Authority
SK
Slovakia
Prior art keywords
src
protein
yes
nucleic acid
pharmaceutical composition
Prior art date
Application number
SK849-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK8492002A3 (en
Inventor
David A. Cheresh
Brian Eliceiri
Robert Paul
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/470,881 external-priority patent/US6685938B1/en
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of SK8492002A3 publication Critical patent/SK8492002A3/sk
Publication of SK287575B6 publication Critical patent/SK287575B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0271Chimeric vertebrates, e.g. comprising exogenous cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Husbandry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK849-2002A 1999-12-22 2000-12-22 Farmaceutická kompozícia obsahujúca nukleovú kyselinu, použitie nukleovej kyseliny a výrobný artikel obsahujúci farmaceutickú kompozíciu SK287575B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/470,881 US6685938B1 (en) 1998-05-29 1999-12-22 Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A 2000-03-29 2000-03-29
PCT/US2000/035396 WO2001045751A1 (en) 1999-12-22 2000-12-22 Angiogenesis and vascular permeability modulators and inhibitors

Publications (2)

Publication Number Publication Date
SK8492002A3 SK8492002A3 (en) 2002-11-06
SK287575B6 true SK287575B6 (sk) 2011-03-04

Family

ID=27043259

Family Applications (1)

Application Number Title Priority Date Filing Date
SK849-2002A SK287575B6 (sk) 1999-12-22 2000-12-22 Farmaceutická kompozícia obsahujúca nukleovú kyselinu, použitie nukleovej kyseliny a výrobný artikel obsahujúci farmaceutickú kompozíciu

Country Status (19)

Country Link
EP (2) EP1250155B1 (es)
JP (1) JP2003518077A (es)
KR (1) KR100813818B1 (es)
CN (1) CN1434727A (es)
AT (2) ATE392215T1 (es)
AU (1) AU781444B2 (es)
BR (1) BR0016547A (es)
CA (1) CA2395136A1 (es)
CZ (1) CZ304320B6 (es)
DE (1) DE60038631T2 (es)
DK (2) DK1250155T3 (es)
ES (2) ES2303514T3 (es)
HU (1) HU229628B1 (es)
NO (1) NO20023036L (es)
PL (1) PL356815A1 (es)
PT (2) PT1250155E (es)
RU (1) RU2271216C2 (es)
SK (1) SK287575B6 (es)
WO (1) WO2001045751A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
ATE328888T1 (de) 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
WO2003079936A1 (en) * 2002-03-18 2003-10-02 Medtronic Ave Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
WO2004006947A1 (en) * 2002-07-12 2004-01-22 Yihai Cao A method for inhibiting vascular permeability and tissue edema
EP1413887A1 (en) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Inhibitors of Src kinase for use in Alzheimer's disease
WO2004056386A2 (en) * 2002-12-19 2004-07-08 To-Bbb Holding B.V. Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
AU2005209231B8 (en) * 2004-01-21 2011-07-28 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
EP1965762A1 (en) * 2005-12-23 2008-09-10 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
CN104689300B (zh) * 2006-05-22 2018-06-05 加利福尼亚大学董事会 用于氧输送的组合物及方法
DE602006004196D1 (de) * 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
EP2495242B1 (en) * 2009-10-29 2016-05-04 Industry-Academic Cooperation Foundation Yonsei University Novel vascular leak inhibitor
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
WO2014152122A2 (en) * 2013-03-15 2014-09-25 Children's Medical Center Corporation Methods of altering vascular permeability and uses thereof
CN105311645B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用
CN105288654B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DE69131255T2 (de) * 1990-01-26 1999-12-16 Washington Research Foundation, Seattle Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
EP0984930B1 (en) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CN1278724A (zh) * 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2-c]吡唑衍生物
PT1082415E (pt) * 1998-05-29 2011-07-04 Scripps Research Inst Métodos úteis para modulação de angiogénese utilizando tirosina-quinase src
BR9915139A (pt) * 1998-11-06 2001-08-07 Basf Ag Método de inibir a hiperpermeabilidade vascular, e de inibir um processo ou estado fisiológico em um indivìduo

Also Published As

Publication number Publication date
CN1434727A (zh) 2003-08-06
HUP0203957A2 (hu) 2003-03-28
DK1905457T3 (da) 2012-05-29
HUP0203957A3 (en) 2005-07-28
BR0016547A (pt) 2002-10-29
PL356815A1 (en) 2004-07-12
DE60038631T2 (de) 2009-06-10
EP1905457B1 (en) 2012-04-18
EP1250155A1 (en) 2002-10-23
AU2740001A (en) 2001-07-03
SK8492002A3 (en) 2002-11-06
DK1250155T3 (da) 2008-08-25
JP2003518077A (ja) 2003-06-03
NO20023036L (no) 2002-07-22
KR100813818B1 (ko) 2008-03-17
ES2303514T3 (es) 2008-08-16
DE60038631D1 (de) 2008-05-29
EP1250155B1 (en) 2008-04-16
HU229628B1 (en) 2014-03-28
RU2271216C2 (ru) 2006-03-10
RU2002119399A (ru) 2004-02-27
PT1250155E (pt) 2008-06-06
AU781444B2 (en) 2005-05-26
EP1250155A4 (en) 2003-08-20
CZ304320B6 (cs) 2014-03-05
ATE553782T1 (de) 2012-05-15
EP1905457A1 (en) 2008-04-02
WO2001045751A1 (en) 2001-06-28
ATE392215T1 (de) 2008-05-15
ES2383763T3 (es) 2012-06-26
NO20023036D0 (no) 2002-06-21
PT1905457E (pt) 2012-05-25
KR20020063259A (ko) 2002-08-01
CA2395136A1 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
US7585841B2 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src
AU781444B2 (en) Angiogenesis and vascular permeability modulators and inhibitors
US20060040853A1 (en) Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras
MXPA02006207A (es) Angiogenesis y moduladores e inhibidores de la permeabilidad vascular
ZA200201761B (en) Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras.

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20161222